Codexis to Highlight Innovations in siRNA Manufacturing at TIDES
Codexis Showcases Innovations in siRNA Manufacturing
Codexis, Inc. (NASDAQ: CDXS), a leader in enzymatic solutions for scalable therapeutics manufacturing, is preparing to showcase its innovative ECO Synthesis platform at the upcoming TIDES USA annual meeting. This event, which brings together professionals in the field, will take place soon, and Codexis is excited to present its latest advancements focusing on siRNA manufacturing.
Highlighting Recent Developments
The Codexis team will showcase essential data that illustrates the efficiency and reproducibility of its enzymatic processes for synthesizing siRNA. With a commitment to enhancing the scalability of RNAi therapeutics, the presentations will delve into a variety of topics, including:
Demonstrating Scalability and Reproducibility
One of the focal points of the presentation will be on the scalability of the ECO Synthesis manufacturing processes. These processes have been designed to ensure that production can meet the demands of the market while maintaining high-quality standards.
Innovative Machine Learning Tools
Another key presentation will introduce an innovative machine learning tool developed by Codexis. This cutting-edge application aids in optimizing ligase selection and fragment design, which is vital for effective siRNA synthesis.
Advancing Stereochemistry Control
Moreover, Codexis will highlight an emerging capability that allows control over stereochemistry during the oligonucleotide synthesis. This exciting breakthrough enhances the precision of synthesized RNA molecules, promising better outcomes in therapeutic applications.
Collaborative Efforts with CDMOs
Three prominent contract development and manufacturing organizations (CDMOs) will also be presenting data on how Codexis' double-stranded RNA ligases effectively combine short RNA fragments. This collaborative effort includes a co-presentation by Bachem and Codexis, showcasing the potential of working together in enhancing RNA technologies.
Engage with Codexis at the Conference
During the TIDES USA Annual Meeting, attendees are encouraged to interact with the Codexis team at Booth #619 in the exhibition hall. This meeting serves as a great opportunity to discuss advancements and explore collaboration possibilities in the RNA therapeutics space.
Oral and Poster Presentations
Codexis is set to feature two oral presentations on important topics in oligonucleotide CMC and a comparative analysis of diastereomeric distribution.
Main Stage Talk:
Oligonucleotide CMC for Sustainable and Scalable Enzymatic siRNA Manufacturing
Speaker: Alison Moore, PhD, Chief Technical Officer
Time: 9:30 am – 10:00 am PT
TIDES Talk:
Comparative Analysis of Diastereomeric Distribution in siRNA Synthesis
Speaker: Stephanie Forget, PhD, Senior Scientist, Protein Engineering
Time: 10:10 am – 10:20 am PT
Co-Presentation with Bachem:
Efficient Large-scale siRNA Manufacturing:
Speakers: Arne Berthelmann, PhD, and Mathew Miller, PhD
Time: 12:05 – 12:35 pm PT
In addition, a poster presentation titled "Machine Learning-Guided Ligation Fragment Design for Efficient siRNA Synthesis" will be available throughout the conference, featuring insights from Codexis’ Director, Mathew Miller, PhD.
Upcoming Conference Call
To further discuss these exciting developments, Codexis management will hold a conference call for interested parties to join the conversation. This call is scheduled for 8:00 am Eastern Time. Participants can dial in to listen to key updates and insights gained from the conference.
About Codexis
Codexis stands at the forefront of enzymatic solutions for therapeutic manufacturing. Utilizing its proprietary CodeEvolver® technology, Codexis is committed to developing high-performance enzymes that address challenges in small molecule pharmaceuticals and nucleic acid synthesis. The ECO Synthesis™ platform particularly emphasizes the sustainable manufacture of RNAi therapeutics, promising a more environmentally friendly approach with improved efficiency and yield.
Frequently Asked Questions
What is the purpose of the TIDES USA Annual Meeting?
The TIDES USA Annual Meeting focuses on advancements in RNA and oligonucleotide technologies, gathering professionals to share innovations and research.
What topics will Codexis present at the conference?
Codexis will present on scalability in siRNA manufacturing, machine learning applications, and stereochemistry control in oligonucleotide synthesis.
How can attendees engage with Codexis at the event?
Attendees can visit Booth #619 to interact with the Codexis team and discuss potential collaborations.
Who are some of the speakers representing Codexis?
Codexis speakers include Alison Moore, PhD, and Mathew Miller, PhD, who will present on various topics.
What is the significance of the ECO Synthesis platform?
The ECO Synthesis platform is designed to enhance the manufacturing of RNAi therapeutics sustainably, focusing on efficiency and reduced waste.
About The Author
Contact Thomas Cooper privately here. Or send an email with ATTN: Thomas Cooper as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.